Embassy Suites by Hilton – Philadelphia Airport
9000 Bartram Avenue, Philadelphia, Pennsylvania 19153 USA
TEL: +1 – 215 – 365-4500 * FAX: +1 – 215 – 365 – 3195
Dale Gerding, MD, FACP, FIDSA
Dr. Gerding, MD, FACP, FIDSA, Conference Chair, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA.
Presentation Topic: TBA
Dr. Mark Wilcox, M.D., FRCPath, Conference Chair, serves as a Consultant Microbiologist, Head & Professor of Medical and Academic Lead of Pathology/Clinical Director of Pathology, at the Leeds Teaching Hospitals (LTHT). Dr. Wilcox is a Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences and is the lead on Clostridium difficile for Public Health England in the UK. Dr. Wilcox serves as the Principal/UK Investigator for several
Mark Wilcox, MD joins fellow Conference Chair, Dale Gerding, MD, FACP, FIDSA and world-renowned topic experts to discuss the burden of C. difficile infections with the risk factors pertaining to current and emerging treatment options along with the importance of applying evidence-based clinical approaches to the prevention of a C. difficile infection (CDI), one of the leading community and healthcare-associated infections, Microbiome research, and much more.
Presentation Topic: TBA
Paul Feuerstadt, MD, FACG
Dr. Feuerstadt, MD, FACG, is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training,
Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training.His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr.Feuerstadt is affiliated with St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT
Presentation Topic: ““C. difficile Infection: Life Cycle, Incidence and Burden.”
Edmond A. Hooker, MD, DrPH
Dr. Hooker, MD, DrPH, received his B.S. degree from Hampden-Sydney College in Virginia. He earned his M.D. degree from Eastern Virginia Medical School. He then completed his residency training in Emergency Medicine at the University of Louisville. As a full-time faculty member at the University of Louisville from 1991 until 1996, Dr. Hooker served as an Associate Professor and Director of Resident Research. He was very active in brain trauma and stroke research. After leaving the University of Louisville, he worked in Virginia and was on faculty at the University of Virginia. He moved to Cincinnati in 1998. Dr. Hooker works clinically in the emergency department at the University of Cincinnati Hospital, serves as Residency Research Director, and directs the Clinical Research Coordinator’s program. Dr. Hooker serves as a medical advisor to Trinity Guardion. Since 2003, Dr. Hooker has been teaching in the Department of Health Services Administration at Xavier University. In the spring of 2007, Dr. Hooker earned his Doctorate in Public Health from the University of Kentucky. In 2015, he was promoted to Professor. Dr. Hooker continues to be active in emergency medicine and public health research.
Presentation Topic: ”Understanding Why Current Methods of Healthcare Disinfection are Failing Our Patients”
Stuart B. Johnson, MD,FIDSA, DTM&H
Dr. Johnson, MD,FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus has involved the epidemiology pathogenesis, and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Presentation Topic: “Review of the Clostridium difficile Guidelines for Adults and Children 2017 Update by IDSA and SHEA.”
Sahil Khanna, MD
Dr. Khanna, MD is an Assistant Professor of Medicine in the Division of Gastroenterolgy and Hepatology at Mayo Clinic, Rochester, MN. His completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at University of California, San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty. Dr. Khanna has completed Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations. He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials at the May Clinic, Rochester, MN.
Presentation Topic: TBA
Nicola Petrosillo, MD, FESCMID
Dr. Petrosillo, MD,FESCMID earned a degree of Doctor in Medicine and Surgery from the University “La Sapienza” in Rome, Italy in 1977; in the same University, he became specialist in Infectious Diseases (1981) and in Internal Medicine (1985). In 1981, he became hospital infectious diseases registrar and in 1999 Director of an Infectious Diseases Division at the National Institute for Infectious Diseases “Lazzaro Spallanzani” of Rome, Italy.He is fellow of the Pulmonary Vascular Research Institute and leader of the international task-force for pulmonary hypertension associated with HIV, since 2007. He is member of the Professional Affairs SubCommittee on Infectious Diseases and member of the Advisory Board of the Trainee Association of ESCMID. Additionally, he is Professor of Infectious Diseases at the Medical School of Specialization in Hygiene of the Tor Vergata University, Rome, and presently Director, Clinical & Research Department for Infectious Diseases National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS.
Presentation Topic: TBA
Norman B. Javitt, MD, Ph.D.
Dr. Norman Javitt, MD is a research doctor in New York, New York. He received his medical degree from Duke University School of Medicine and has been in practice for more than 20 years. Education and Medical Training: Mount Sinai School of Medicine ,Residency , Internal Medicine,Mount Sinai School of Medicine Residency , Internal Medicine, Mount Sinai School of Medicine ,Internship , Transitional Year Duke University School of Medicine Medical School. Elected Member The American Society for
Clinical Investigation, 1969.
PresentationTopic: “Ursodeoxycholic Acid Bridge” Therapy for the Prevention and Treatment of Clostridium difficile Infection.”
Nick Van Hise, PharmD, BCPS
Nick Van Hise, PharmD, received a Bachelor of Science from Bradley University in Peoria, IL and his Doctorate of Pharmacy from Union University School of Pharmacy in Jackson, TN.Dr. Van Hise then went on to do an infectious disease residency and become board certified in pharmacoltherapy and infectious disease. Dr. Van Hise has been published in various scientific journals, includng the New England Journal of Medicine, Clinical Infectious Diseases, and the Journal of Clinical Neuropharmacology.
Presentation Topic: TBA
C. diff. Survivors
Mr. Roy Poole and Mrs. Kathy Bischoff – C. diff. Survivors — join us to share their personal C. difficile infection journey; The signs, symptoms, treatments, with the physical, mental, and psycho-social changes endured from this life-threatening infection and how each recurrent C. difficile infection (rCDI) impacted their lives.
Presentation Topic: “A C. diff. Survivor’s Journey.”
Simon M. Cutting, Ph.D.
Professor Cutting of Molecular Microbiology at Royal Holloway, University of London is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus Clostridium difficile.. His other expertise is in the use of Bacillus spores as probiotics and has a number of contracts and consultancies with European and US companies in the food and feed sectors.
Presentation Topic: “New Insights To the Causes of Clostridium difficile Infections.”
Maureen Spencer, RN, M.Ed.
Maureen Spencer, RN, M.Ed. has been board certified in infection control (CIC) for over 30 years and is currently the Director, Clinical Implementation at Accelerate Diagnostics, providing educational and consultative services to the sales and marketing teams in the US. She was previously the Corporate Director, Infection Prevention for Universal Health Services in King of Prussia, PA, Infection Control Manager at New England Baptist Hospital, Director Infection Control Unit at Mass General Hospital and other Boston hospitals in a career that has spanned
over 40 years.
Presentation Topic: ““Prevention of Antimicrobial Resistance, Sepsis and Antibiotic Side Effects with Fast Molecular Diagnostics for Bloodstream Infections.”
Joseph Sliman, MD,MPH
Dr. Sliman, MD, MPH, is Chief Medical Officer and joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master’s Degree in Public Health from the Johns Hopkins University School of Public Health, and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University
Presentation Topic: TBA
Mary Beth Dorr, PhD
Dr. Mary Beth Dorr is the product development lead for ZINPLAVA (bezlotoxumab), a monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Mary Beth has a pharmacy degree from the University of the Sciences’ Philadelphia College of Pharmacy and completed a clinical pharmacy residency at the Veteran’s Administration Hospital in Philadelphia. She received a PhD in pharmaceutics with an emphasis on pharmacokinetics and drug metabolism at the University of North Carolina Chapel Hill. Mary Beth joined the pharmaceutical industry in 1988, and has held a variety of positions related to the design and implementation of Phase 1 to 4 clinical trials, primarily for anti-infective products. Mary Beth has wide-ranging drug-development experience at several pharmaceutical companies, including Parke-Davis/Warner Lambert, Rhone-Poulenc Rorer/Aventis, Vicuron, and Wyeth/Pfizer, where she worked in pharmacokinetics/drug metabolism, clinical research, project and alliance management, and medical affairs. Mary Beth joined Merck in 2011 to direct the C. difficile monoclonal antibody clinical development program and led the clinical team through product registration and launch. In addition to her role as the product development team lead, she is responsible for the bezlotoxumab publication strategy and is the clinical director for the pediatric development program for bezlotoxumab.
Presentation Topic: “Bezlotoxumab Subgroup Analyses: Patients at High Risk for CDI Recurrence.”
Stephen Marcella, MD
Dr. Marcella, MD is a clinician trained in internal medicine and pediatrics. After serving in the National Health Service for 4 years and then as a faculty member of a primary care residency, he became interested in clinical epidemiology. Having obtained an MPH from Rutgers in NJ, he spent the next 15 years doing epidemiology research, teaching medical and graduate students, supervising medicine residents, and seeing patients in a federally qualified health care clinic associated with the Robert Wood Johnson Medical School. His research interests have focused largely on prevention and screening and he directed a large NIH-funded study of PSA testing and prostate cancer mortality in New Jersey. He continues to teach at the Rutgers School of Health as an adjunct professor. For the last four years, Steve has been working as a director in outcomes research at Merck. In the last two years, he has been working on quantifying the burden of illness from CDI and recurrent CDI as well as the health economic data behind Merck’s new product that reduces the recurrence of CDI. This work incorporates elements of health economics, epidemiology, and real world evidence.
Presentation Topic: ” Early Real-World Evidence of bezlotoxumab Effectiveness As Used In U.S, Infusion Centers.”
Joe Martin, Executive Director, Pennsylvania Health Care Cost Containment Council (PHC4) Mr. Martin, who joined PHC4 in 1991, was appointed to the Executive Director position on November 5, 2009. In this role, he provides leadership to a professional and technical staff of 28 and is responsible for overseeing all agency operations, including the planning, directing, coordinating and executing of all PHC4 initiatives. He also works with a 25-member Council to set policy and work priorities as well as to plan and implement the future direction for PHC4.
Presentation Topic: “Higher Costs and Worse Outcomes for Patients Hospitalized with a Clostridium difficile Infection.”
Barley Chironda,, RPN, CIC.
Barley Chironda, a Nurse, is the Social Media Manager of IPAC Canada and the Past President of IPAC- GTA. He is also the National Healthcare Sales Director and Infection Control Specialist with Clorox Canada. He is certified in Infection prevention and control (CIC™) and has worked extensively as in Infection Control. He is typically found engaged in motivating hospital staff, patients and the public on proper infection prevention practices. His roles allow great participation in quality improvement interventions related to patient and public safety. Therefore Barley has been an integral to the successful decline in Clostridium difficile infections through implementing innovative technology and quality improvement behavioural change. He takes pride in sharing information via social media and is often engaging the public on Twitter™ and LinkedIn™, partaking in resource distribution related to innovative and novel Infection prevention strategies. Barley also volunteers as the Infection Control Specialist with the C Diff Foundation.
Presentation Topic: TBA
Guest Speakers Will Be Added Monthly Until Final Program.
The C Diff Foundation welcomed members of the Media to the
6th Annual International C. diff. Awareness Conference and Health EXPO
November 8 and 9, 2018 at the Embassy Suites by Hilton Philadelphia PA
Qualifications and guidelines
Registration is complimentary for professional journalists attending the conference
to provide editorial coverage and who meet the eligibility criteria.
Please contact the C Diff Foundation firstname.lastname@example.org
Follow us on Twitter